Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Clin Cancer Res (2016) 22 (19): 4837–4847.

https://doi.org/10.1158/1078-0432.CCR-15-1915

Published: 02 October 2016

View article titled, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Includes: Supplementary data

Journal Articles

AACR Cancer Progress Report 2016

Nancy E. Davidson, Scott A. Armstrong, Lisa M. Coussens, Marcia R. Cruz-Correa, Ralph J. DeBerardinis, James H. Doroshow, Margaret Foti, Patrick Hwu, Thomas W. Kensler, Monica Morrow, Charles G. Mulligan, William Pao, Elizabeth A. Platz, Thomas J. Smith, Cheryl L. Willman

Clin Cancer Res (2016) 22 (19_Supplement): S1–S137.

https://doi.org/10.1158/1078-0432.CCR-16-1993

Published: 02 October 2016

View article titled, AACR Cancer Progress Report 2016

Journal Articles

Abstract A18: A novel targeted capture and massively parallel sequencing platform for systematic discovery of tyrosine kinase fusions in cancer

Juliann Chmielecki, Martin Peifer, Peilin Jia, Nicholas D. Socci, Katherine Hutchinson, Agnes Viale, Zhongming Zhao, Roman K. Thomas, William Pao

Clin Cancer Res (2010) 16 (7_Supplement): A18.

https://doi.org/10.1158/1078-0432.TCME10-A18

Published: 02 February 2016

View article titled, Abstract A18: A novel targeted capture and massively parallel sequencing platform for systematic discovery of tyrosine kinase fusions in cancer

Journal Articles

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi

Clin Cancer Res (2016) 22 (2): 426–435.

https://doi.org/10.1158/1078-0432.CCR-15-0620

Published: 14 January 2016

View article titled, Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Includes: Supplementary data

Journal Articles

Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC

Cath Eberlein, Katie Al-Kadhimi, Sarah Ross, Henry Brown, Paul Fisher, Daniel Stetson, Zhongwu Lai, Kenneth Thress, Brian Dougherty, William Pao, Darren Cross

Clin Cancer Res (2015) 21 (4_Supplement): PR05.

https://doi.org/10.1158/1557-3265.PMS14-PR05

Published: 13 February 2015

View article titled, Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC

Journal Articles

Melanoma BRAF Fusions—Response

Katherine E. Hutchinson, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Jeffrey A. Sosman, William Pao

Clin Cancer Res (2014) 20 (24): 6632.

https://doi.org/10.1158/1078-0432.CCR-14-1152

Published: 14 December 2014

View article titled, Melanoma BRAF Fusions—Response

Journal Articles

Elucidating Mechanisms of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

William Pao

Clin Cancer Res (2007) 13 (19_Supplement): PL08-02.

Published: 15 August 2014

View article titled, Elucidating Mechanisms of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Journal Articles

FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang, Lei Wang, Yuan Li, Haichuan Hu, Lei Shen, Xuxia Shen, Yunjian Pan, Ting Ye, Yang Zhang, Xiaoyang Luo, Yiliang Zhang, Bin Pan, Bin Li, Hang Li, Jie Zhang, William Pao, Hongbin Ji, Yihua Sun, Haiquan Chen

Clin Cancer Res (2014) 20 (15): 4107–4114.

https://doi.org/10.1158/1078-0432.CCR-14-0284

Published: 31 July 2014

View article titled, FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

Catherine B. Meador, Christine M. Micheel, Mia A. Levy, Christine M. Lovly, Leora Horn, Jeremy L. Warner, Douglas B. Johnson, Zhongming Zhao, Ingrid A. Anderson, Jeffrey A. Sosman, Cindy L. Vnencak-Jones, Kimberly B. Dahlman, William Pao

Clin Cancer Res (2014) 20 (9): 2264–2275.

https://doi.org/10.1158/1078-0432.CCR-13-1591

Published: 30 April 2014

View article titled, Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

Journal Articles

Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

Catherine B. Meador, Hailing Jin, Elisa de Stanchina, Valentina Pirazzoli, Marc Ladanyi, Lu Wang, Xi Chen, Rosana Eisenberg, Darren Cross, William Pao

Clin Cancer Res (2014) 20 (2_Supplement): B10.

https://doi.org/10.1158/1078-0432.14AACRIASLC-B10

Published: 16 January 2014

View article titled, Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

Journal Articles

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

Katherine E. Hutchinson, Doron Lipson, Philip J. Stephens, Geoff Otto, Brian D. Lehmann, Pamela L. Lyle, Cindy L. Vnencak-Jones, Jeffrey S. Ross, Jennifer A. Pietenpol, Jeffrey A. Sosman, Igor Puzanov, Vincent A. Miller, William Pao

Clin Cancer Res (2013) 19 (24): 6696–6702.

https://doi.org/10.1158/1078-0432.CCR-13-1746

Published: 16 December 2013

View article titled, BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

Includes: Supplementary data

Journal Articles

Characteristics of Lung Cancers Harboring NRAS Mutations

Clin Cancer Res (2013) 19 (9): 2584–2591.

https://doi.org/10.1158/1078-0432.CCR-12-3173

Published: 30 April 2013

View article titled, Characteristics of Lung Cancers Harboring NRAS Mutations

Includes: Supplementary data

Journal Articles

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely

Clin Cancer Res (2013) 19 (8): 2240–2247.

https://doi.org/10.1158/1078-0432.CCR-12-2246

Published: 15 April 2013

View article titled, Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Journal Articles

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

Paul Yeh, Heidi Chen, Jenny Andrews, Riyad Naser, William Pao, Leora Horn

Clin Cancer Res (2013) 19 (7): 1894–1901.

https://doi.org/10.1158/1078-0432.CCR-12-1894

Published: 02 April 2013

View article titled, DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

Includes: Supplementary data

Journal Articles

Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer

Ken Takezawa, Mary Ann Melnick, Greg Riely, Mark Kris, Vincent Miller, Marc Ladanyi, Katerina Politi, William Pao, Valentina Pirazzoli, Xiaoling Song, Maria Arcila, Elisa De Stanchina, Kadoaki Ohashi, Yelena Janjigian, Paula Spitzler, Caroline Nebhan

Clin Cancer Res (2012) 18 (10_Supplement): A23.

https://doi.org/10.1158/1078-0432.MECHRES-A23

Published: 04 March 2013

View article titled, Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer

Journal Articles

Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

Valentina Pirazzoli, Ken Takezawa, Elisa de Stanchina, William Pao, Katerina Politi

Clin Cancer Res (2012) 18 (10_Supplement): A38.

https://doi.org/10.1158/1078-0432.MECHRES-A38

Published: 04 March 2013

View article titled, Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

Journal Articles

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Johannes M. Heuckmann, Hyatt Balke-Want, Florian Malchers, Martin Peifer, Martin L. Sos, Mirjam Koker, Lydia Meder, Christine M. Lovly, Lukas C. Heukamp, William Pao, Ralf Küppers, Roman K. Thomas

Clin Cancer Res (2012) 18 (17): 4682–4690.

https://doi.org/10.1158/1078-0432.CCR-11-3260

Published: 30 August 2012

View article titled, Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Includes: Supplementary data

Journal Articles

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu, Hang Li, Lei Wang, William Pao, Haiquan Chen

Clin Cancer Res (2012) 18 (7): 1947–1953.

https://doi.org/10.1158/1078-0432.CCR-11-2511

Published: 01 April 2012

View article titled, Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

Includes: Supplementary data

Journal Articles

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Johannes M. Heuckmann, Michael Hölzel, Martin L. Sos, Stefanie Heynck, Hyatt Balke-Want, Mirjam Koker, Martin Peifer, Jonathan Weiss, Christine M. Lovly, Christian Grütter, Daniel Rauh, William Pao, Roman K. Thomas

Clin Cancer Res (2011) 17 (23): 7394–7401.

https://doi.org/10.1158/1078-0432.CCR-11-1648

Published: 30 November 2011

View article titled, ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Includes: Supplementary data

Journal Articles

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller

Clin Cancer Res (2011) 17 (19): 6322–6328.

https://doi.org/10.1158/1078-0432.CCR-11-1080

Published: 02 October 2011

View article titled, Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

Includes: Supplementary data

NARROW

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

AACR Cancer Progress Report 2016

Abstract A18: A novel targeted capture and massively parallel sequencing platform for systematic discovery of tyrosine kinase fusions in cancer

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC

Melanoma BRAF Fusions—Response

Elucidating Mechanisms of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

Characteristics of Lung Cancers Harboring NRAS Mutations

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer

Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only